Project Details
Description
Project Summary
Oncogenic or tumor suppressive signaling often causes imbalances in posttranslational modifications (PTMs)
in human cancer. The receptor tyrosine kinase HER2 is an oncogene amplified or overexpressed in
approximately 25% of breast cancers and is associated with tumor aggressiveness and poor prognosis. A
recent study demonstrated that HER2 is translocated to mitochondria in a kinase activity-dependent manner to
alter metabolism and promote drug resistance in breast cancer cells. Consistent with these findings, our recent
study showed that oncogenic fibroblast growth factor receptor (FGFR) 1, which is also localized in
mitochondria, directly tyrosine phosphorylates mitochondrial pyruvate dehydrogenase kinase (PDHK) 1,
enhancing its enzyme activity to promote tumor growth in mice. Taken together, these results strongly suggest
that mitochondrial localization of oncogenic tyrosine kinases, including HER2, regulate mitochondrial metabolic
pathways that contribute to tumor growth. However, which mitochondrial metabolic enzymes are regulated by
HER2 in breast cancer is totally unknown. Thus, we performed phospho-proteomic analyses of mitochondria-
enriched fractions from HER2+ BT474 breast cancer cells and found that mitochondrial carnitine
palmitoyltransferase (CPT) 1A is tyrosine phosphorylated at Y514. Further biochemical analyses showed that
CPT1A Y514 phosphorylation by HER2 promotes its carnitine palmitoyltransferase (CPTase) activity.
Interestingly, we recently found that CPT1A has an additional enzymatic activity as a lysine succinyltransferase
(LSTase) to succinylate lysine residues of substrate proteins in vitro and in vivo .To our knowledge, CPT1A is a
first and only LSTase in mammalian cells. Importantly, mutation of CPT1A Gly710 (G710E) selectively
inactivated CPTase activity but not LSTase activity. Similar to CPT1A WT, CPT1A G710E increased total
lysine succinylation in cells without affecting intracellular succinyl-CoA levels. These findings suggest the
unprecedented role of CPT1A as LSTase that can regulate lysine succinylation-dependent signal transduction
in cells independent of its canonical CPTase activity that facilitates mitochondrial fatty acid oxidation (FAO)
pathway. Notably, however, how the LSTase activity of CPT1A is regulated and whether LSTase activity is
important for tumorigenesis is not known. Previous studies reported that multiple types of cancers including
melanoma, prostate, breast, and ovarian cancers showed elevated expression of CPT1A and knockdown of
CPT1A with si/shRNAs decreased cancer cell proliferation. We also found that high CPT1A mRNA expression
in HER2+ breast cancer patients strongly correlates with reduced survival while no correlation between CPT1A
mRNA expression and reduced patient survival was observed in other types of breast tumors. In addition, we
found that knockdown of CPT1A, as well as inhibition of HER2 by lapatinib, decreased CPT1A-subsrate motif
LVxxK succinylation and suppressed BT474 cell proliferation. These results suggest a link between CPT1A
LSTase activity and HER2 signaling in regulation of breast cancer cell proliferation. We thus hypothesize that
HER2-mediated phosphorylation of CPT1A at Y514 may promote its LSTase activity in addition to the
canonical CPTase activity to reprogram metabolism, thereby increasing tumor proliferation. To address this,
we propose in Aim 1 to examine how HER2-dependent CPT1A Y514 phosphorylation affects its dual
enzymatic activities. In Aim 2, we will examine whether either or both of the novel LSTase and canonical
CPTase activities of CPT1A alter breast cancer metabolism. In Aim 3, we will examine whether the LSTase
activity of CPT1A promotes breast cancer cell proliferation and tumor growth via CPT1A Y514 phosphorylation.
Overall, the proposed studies will shed new mechanistic insight into the role of the dual enzymatic activities
(LSTase and CPTase activities) of CPT1A in HER2+ breast tumorigenesis and provide the comprehensive
understanding of how two distinct PTMs (tyrosine phosphorylation and lysine succinylation) are coordinated to
alter metabolism through the signaling hub protein CPT1A to promote tumor growth.
Status | Finished |
---|---|
Effective start/end date | 4/1/18 → 3/31/24 |
Funding
- National Cancer Institute: $363,713.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.